InMed Pharmaceuticals

Fierce Biotech #Alzheimers #Webinar SPEAKER SPOTLIGHT! Dr. Phyllis Ferrell, Chief Impact Officer of StartUp Health's Alzheimer's Moonshot moderates this webinar discussion on innovation in #AlzheimersDisease research. The panel will talk about the effects of #neuroinflammation on Alzheimer's disease development and progression and new pathological targets. Alzheimer’s Outlook - Neuroinflammation, the Next Step November 12, 2024, 2:00pm Register here: https://lnkd.in/g5QBdUm4 $INM #research 

InMed expands patent application for INM-901 Alzheimer's disease drug candidate. “The INM-901 drug development program represents a novel approach to treating Alzheimer’s disease and the conversion of this PCT application is an important step to protect our research and development in the area of neurodegeneration. We have recently made significant progress with the INM-901 and are committed to advancing this program towards human clinical trials. We look forward to presenting long-term in vivo data in the coming weeks." Full news release: https://ow.ly/MTS950TUMtt $INM #AlzheimersDisease #patent #neurodegeneration

What have we learned about #Alzheimer’s disease over the last five years? What are the next developments? A panel of #AlzheimersDisease experts will come together on Nov 12th in a Fierce Biotech #webinar to talk about the latest #Alzheimers research and the effects of #neuroinflammation. Register FREE to join Dr. Phyllis Ferrell of StartUp Health #AlzMoonshot, Dr. Dave Morgan of Michigan State University, Dr. Marwan Sabbagh of Barrow Neurological Institute, Dr. Barry Greenberg of The Johns Hopkins University School of Medicine, and Dr. Eric Hsu of InMed Pharmaceuticals in this insightful conversation. More here: https://lnkd.in/gb_PiQqs Meet the speakers: Phyllis Ferrell, DrPH, MBA (Moderator) Dr. Phyllis Ferrell is the Chief Impact Officer at StartUp Health’s Alzheimer’s Moonshot. Formerly, she was the Global Head of External Engagement for Alzheimer’s disease and neurodegeneration at Eli Lilly & Company, where she previously served as the leader of the Global Alzheimer’s disease development team. Barry Greenberg, PhD Dr. Greenberg is an Associate Professor in the Department of Neurology at the Johns Hopkins University School of Medicine, where he is leading the development of an Alzheimer’s Disease Translational Center, with the objective of integrating basic and clinical research to enable the development of effective therapies that will delay or prevent Alzheimer’s at its earliest stages. He is also Editor-in-Chief of the journal “Alzheimer’s & Dementia: Translational Research and Clinical Interventions.” David Morgan, PhD Dr. Morgan is Director of the Alzheimer’s Alliance and MSU Foundation Professor of Translational Neuroscience at Michigan State University. Dr. Morgan’s research interests are Alzheimer’s disease, aging and brain function. He is internationally recognized for his work on immunotherapy and gene therapy to treat Alzheimer-related pathologies. Marwan Sabbagh, MD Dr. Sabbagh is the Moreno Family Chair for Alzheimer’s Research and Vice Chairman for Research and Professor of Neurology at the Barrow Neurological Institute in Phoenix Arizona. Dr. Sabbagh is first and foremost an experienced clinician, whose practice as a geriatric neurologist is world renowned. He has also been a leading investigator for Alzheimer’s clinical trials for over 25 years. Eric Hsu, PhD Dr. Hsu is the Senior Vice President of Preclinical Research and Development at InMed Pharmaceuticals where he leads the Alzheimer’s disease R&D program. He has 20+ years of research experience and is an expert in gene transfer and gene expression. $INM #Alzheimers #AlzheimersResearch

InMed has filed an additional international #patent application focused on the #pharmaceutical composition and method of use for the proprietary small molecule drug candidate INM-901 for treating #neurodegenerative diseases, including #Alzheimer’s disease. This PCT patent application encompasses several key components, including: •treatment of #neuronal disorders, particularly those associated with #neurodegeneration •potential to inhibit or slow the progression of neurodegenerative diseases by reducing cytotoxicity in affected neuron populations •use in promoting #neurite elongation and/or restoring neurite formation in damaged neurons News release here: https://ow.ly/NiWl50TTOnR $INM #Alzheimers #AlzheimersDisease

#NEWS: InMed Pharmaceuticals Files Additional #Patent Application for INM-901 in the Treatment of #Neurodegenerative Conditions Including #Alzheimers Disease Full news release: https://lnkd.in/gqGarp5w $INM

InMed to Participate in Fierce Biotech Biotech Webinar on Neuroinflammation in Alzheimer’s Disease Nov 12th, 2pm ET Details on how to register: https://ow.ly/mlXw50TSaal $INM #Alzheimers #webinar

Fierce Biotech #WEBINAR #Alzheimers Alzheimer’s Outlook - Neuroinflammation, the Next Step Date: November 12, 2024 Time: 2:00pm ET Discussion topics in this webinar include: • the latest research into the causes of #Alzheimer's disease • the different therapeutic pathways being explored • drugs in development and their pharmacological targets • the pathophysiological effects of #neuroinflammation in #AlzheimersDisease Registration: https://ow.ly/j0Sw50TSagN $INM #research

#NEWS: InMed to Participate in Fierce Biotech Webinar on #Neuroinflammation in #Alzheimer’s Disease Nov 12th, 2pm ET Details on how to register: https://ow.ly/uLoa50TSacw $INM #Alzheimers #webinar

The Dales Report Replay: InMed and #Alzheimers Research InMed’s CEO, Eric A. Adams, speaks with The Dales Report about the company’s Alzheimer’s disease in vivo studies. He talks about the need for new treatments to address the multiple pathologies related to this disease, including neuroinflammation. Watch here: https://ow.ly/7hL650TQ7v9 $INM

Dr. Barry Greenberg joins InMed's Scientific Advisory Board Barry Greenberg is an Associate Professor in the Department of Neurology and Director of the Alzheimer’s Disease Translational Center at the Johns Hopkins University School of Medicine. Dr. Greenberg has been involved in Alzheimer’s disease (AD) research and drug discovery since 1985, holding a series of positions internationally. He led a drug discovery team at AstraZeneca and later led the preclinical biology research program at Neurochem in Québec. Dr. Greenberg moved to the University Health Network in Toronto in 2008, as Director of Neuroscience Drug Discovery and Development, where he was responsible for the conceptualization and leadership of the Toronto Dementia Research Alliance. Additionally, he served as Chair of the National Institute on Aging’s international committee, which was charged with strategizing the future structure of the Alzheimer’s Disease Research Center network. Dr. Greenberg moved to Johns Hopkins in 2018 to lead the development of an AD Translational Center, with the objective of integrating basic and clinical research to enable the development of effective therapies that will delay or prevent AD at its earliest stages. He serves on several committees and advisory boards for NIA-funded initiatives focused on genetics, model development and clinical trials in AD, and is Editor-in-Chief of the journal “Alzheimer’s & Dementia: Translational Research and Clinical Interventions.” News release: https://ow.ly/2g9p50TQn0e $INM